1. Classification of Chronic Kidney Disease (CKD)

Epidemiological Significance: CKD affects 10-15% of adults in Western countries, with ~26 million in the USA classified as having CKD and another 20 million at increased risk. CKD is a major independent risk factor for cardiovascular morbidity and mortality.

The classification system for CKD was established by the Kidney Disease Outcomes Quality Initiative (K/DOQI) in 2002 and later refined by Kidney Disease: Improving Global Outcomes (KDIGO) in 2004-2005. It is based primarily on glomerular filtration rate (GFR) regardless of underlying pathology.

1.1 Definition of CKD (KDIGO Criteria)

CKD is defined by either of the following, present for ≥3 months:

  • Kidney damage evidenced by structural/functional abnormalities (pathologic findings, markers in blood/urine, imaging abnormalities) with or without decreased GFR.
  • GFR < 60 mL/min/1.73 m², with or without kidney damage.

1.2 CKD Staging (Modified K/DOQI Classification)

Stage Description GFR (mL/min/1.73m²) Clinical Terms
1 Kidney damage with normal or ↑ GFR ≥ 90 Albuminuria, proteinuria, hematuria
2 Kidney damage with mild ↓ GFR 60 – 89 Albuminuria, proteinuria, hematuria
3 Moderate ↓ GFR 30 – 59 Chronic renal insufficiency
4 Severe ↓ GFR 15 – 29 Late renal insufficiency, pre-ESRD
5 Kidney failure < 15 (or dialysis) End-stage renal disease (ESRD)

Modifiers: "T" for transplant recipients at any GFR, "D" for dialysis-dependent patients (stage 5D). Current critiques note heterogeneity within stages—outcomes vary by age, etiology, CV risk, and progression rate—suggesting future refinements may incorporate these factors.

2. Pathophysiology of Kidney Disease

2.1 Unique Renal Vulnerabilities

  • High renal blood flow (~400 mL/100g tissue/min) increases exposure to circulating toxins.
  • Glomerular hypertension even under physiological conditions predisposes to hemodynamic injury.
  • Negatively charged filtration barrier repels anionic proteins; loss of charge leads to proteinuria.
  • Nephron as a functional unit: Glomerular injury spreads to tubulointerstitium via ultrafiltrate and shared microvasculature.
  • Glomerular cellular interdependence: Injury to one cell type (endothelial, mesangial, podocyte) affects others via mediators and matrix changes.

2.2 Mechanisms of Glomerular Injury

2.2.1 Immunologic Mechanisms

Three broad categories of acquired glomerular disease:

  1. Nonproliferative (minimal change disease, FSGS, membranous nephropathy) – often podocyte-centric.
  2. Proliferative (IgA nephropathy, lupus nephritis, postinfectious GN, anti-GBM disease) – immune complex deposition triggers inflammation.
  3. Glomerular involvement in systemic diseases (diabetic nephropathy, amyloidosis).

Immune complex deposition sites determine response:

  • Subendothelial/Mesangial → Nephritic syndrome (inflammation, leukocyte recruitment).
  • Subepithelial (e.g., membranous nephropathy) → Nephrotic syndrome (limited leukocyte access due to GBM barrier).

Key mediators: Complement (C5-9 MAC), cytokines, chemokines, reactive oxygen species, proteases. T-cells modulate injury and antibody production, especially in pauci-immune GN.

2.2.2 Nonimmunologic Glomerular Injury

  • Hemodynamic: Systemic/glomerular hypertension → mesangial matrix expansion → glomerulosclerosis (mediated by Angiotensin II, TGF-β, PDGF).
  • Metabolic: Hyperglycemia, lipids induce structural/functional changes.

2.3 Mechanisms of Tubulointerstitial Injury

Tubulointerstitial fibrosis (TIF) correlates more strongly with renal functional decline than glomerular injury. TIF involves:

  • Inflammatory cell infiltration (monocytes/macrophages, T-cells)
  • Fibroblast activation → myofibroblast differentiation
  • Epithelial-mesenchymal transition (EMT)
  • Extracellular matrix accumulation (increased synthesis/decreased degradation)
  • Peritubular capillary rarefaction → hypoxia
  • Tubular atrophy (apoptosis)

2.3.1 Key Pathways in Renal Fibrosis

Profibrotic cytokines: TGF-β1 (central), Angiotensin II, CTGF, PDGF, FGF-2.

Hypoxia-inducible factor-1 (HIF-1): Master regulator upregulated in CKD; promotes EMT, fibrosis, and suppresses matrix degradation.

Proteinuria: Direct tubular toxicity, lysosomal overload, induction of chemokines (MCP-1, RANTES), adhesion molecules (ICAM-1, VCAM-1), and TGF-β.

Clinical Correlation: The severity of tubulointerstitial damage, not just glomerular pathology, is a major determinant of CKD progression. Therapeutic strategies targeting fibrosis (e.g., BMP-7, anti-fibrotics) and reducing proteinuria are crucial.

3. Therapeutic Implications for Pharmacy Practice

  • Staging-based interventions: Guidelines exist for dyslipidemia, bone disease, and hypertension at each CKD stage.
  • RAAS inhibition: Cornerstone for reducing proteinuria and slowing progression (targets hemodynamic and fibrotic pathways).
  • Monitoring: GFR, albuminuria, electrolytes, drug dosing adjustments.
  • Emerging targets: TGF-β, CTGF, HIF-1, EMT pathways, matrix metalloproteinases.
  • Individualized care: Account for age, etiology, and comorbidities affecting CKD progression.

Recommended Reading

  • Coresh J, et al. Prevalence of CKD... Am J Kidney Dis 2003.
  • Go AS, et al. CKD and risks of death... NEJM 2004.
  • K/DOQI clinical practice guidelines... Am J Kidney Dis 2002.
  • Levey AS, et al. Definition and classification... Kidney Int 2005.
  • Fine LG, Norman JT. Chronic hypoxia... Kidney Int 2008.
  • Abbate M, et al. How does proteinuria cause damage? JASN 2006.